Ernexa selected for the Emerging Track, recognizing the Company among emerging innovators in the cell and gene therapy sector ...

Cellectis (NASDAQ:CLLS) outlined plans to advance two preclinical in vivo gene-editing candidates for severe forms of dyslipidemia, targeting hypertriglyceridemia and hypercholesterolemia through ...

Indian researchers identified non-tuberculous mycobacteria from bovine clinical samples, finding Mycobacterium vaccae to ...

There’s a fairly universal image of cats and water: the frantic scramble away from a bathtub, the indignant glare after an unexpected raindrop. It’s so well established that it’s practically folklore ...

Gene Munster forecasts 2,200 annual launches by 2030 and says achieving more than 2,000 could more than double the stock.

Ovarian cancer remains the deadliest of the gynecologic malignancies, a distinction earned not because it is the most common ...

Atsena Therapeutics, a Durham, NC-based clinical-stage gene therapy company focused on reversing or preventing blindness from inherited retinal ...

Patent filing covers PH1 payload’s unique ability to disrupt multiple cancer-driving pathways in addition to its overall ...

Genetic medicines and more selective small molecules are finally pushing the field toward new mechanisms — and potentially ...

Dyne Therapeutics is reiterated as a "risky Buy" following a >30% stock decline, presenting a contrarian opportunity. Click ...

Tuesday, Ernexa Therapeutics ( ERNA) said it has been selected for the Emerging Track at the 2026 Cell & Gene Meeting on the Mesa, where CEO Sanjeev Luther will present the company's oncology strategy ...

Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional ...